Pharmacologic Treatment of Schizophrenia Beyond Dopamine Receptor Blockade-Has Its Time Come Yet?

JAMA Psychiatry. 2024 Feb 1;81(2):118-120. doi: 10.1001/jamapsychiatry.2023.4353.

Authors

Christoph U Correll^{1

2}, Leslie Citrome³

Affiliations

¹ Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
² Department of Child and Adolescent Psychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany.
³ Department of Psychiatry & Behavioral Sciences, New York Medical College, Valhalla.

PMID: 38091002
DOI: 10.1001/jamapsychiatry.2023.4353

No abstract available

Plain language summary

This Viewpoint describes the need for novel mechanism of action agents for schizophrenia to extend therapeutic options and improve outcomes.

MeSH terms

Antipsychotic Agents* / therapeutic use
Dopamine
Humans
Receptors, Dopamine* / therapeutic use
Schizophrenia* / drug therapy

Substances

Antipsychotic Agents
Dopamine
Receptors, Dopamine